ArticleMolecular biology reports2025
Interferon-alpha 2b (IFNα2b) enhances monocyte-derived dendritic cell maturation and Th1-skewed anti-tumor immunity in non-small cell lung cancer.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Characterizing risk groups in papillary thyroid carcinoma through T-Cell mediated tumor cell killing-related genes: a pathway to therapeutic predictions.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundDendritic cell (DC) maturation is critical for antitumor immunity. Interferon-alpha 2b (IFNα2b) enhances dendritic cell function; however, its effects on monocyte-derived DCs (Mo-DCs) from NSCLC patients remain unclear. This in vitro experimental study investigates IFNα2b-mediated Mo-DC maturation and immune function in both healthy individuals and NSCLC patients.
methodsPeripheral blood samples were collected from healthy donors (n = 30; 18-65 years; 17 males, 13 females) and newly diagnosed, untreated stage I NSCLC patients (n = 30; 18-65 years; 16 males, 14 females). PBMCs were isolated by density gradient centrifugation, and adherent monocytes were cultured with recombinant human GM-CSF and IL-4 for 3 days to generate immature Mo-DCs. Maturation was induced using IFN-α2b or LPS. Maturation markers, cytokine profiles, and immune cell activation were analyzed using flow cytometry and ELISA. Oxidative stress parameters and functional assays evaluating cytotoxic T lymphocyte (CTL)-mediated killing of NSCLC cells were also performed.
resultsIFNα2b-matured Mo-DCs exhibited significantly increased expression of maturation markers including CD1d, NFκB, STAT3, BATF3, PU.1, and DNAPKcs compared to untreated controls. Co-culture with peripheral blood mononuclear cells (PBMCs) resulted in enhanced NK cell activation (increased CD56 + expression) and promoted a pro-inflammatory Th1-skewed response, characterized by elevated secretion of IL-12, IFNγ, and TNF-α, while T
conclusionIFNα2b enchances dendritic cell maturation and promotes T
Indexed as
Identifiers
41351777What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.